Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | unknown | Early Phase 1 | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626752 | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04412174 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04129099 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT03790891 | Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | unknown | Early Phase 1 | 72 | He HuangOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04169932 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03116659 | CTCL Directed Therapy | unknown | Early Phase 1 | 8 | James J. Peters Veterans Affairs Medical CenterFED | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04011293 | A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | Shandong UniversityOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03690310 | Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03824951 | Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 10 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03824964 | Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 10 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03692767 | Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03228303 | Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Early Phase 1 | 100 | Assiut UniversityOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Nov 13, 2020source: clinicaltrials